Literature DB >> 36134085

Hepatic Encephalopathy and Treatment Modalities: A Review Article.

Kapil Sharma1, Shivani Akre1, Swarupa Chakole2, Mayur B Wanjari3.   

Abstract

Hepatic encephalopathy (HE) is a condition that is commonly seen in individuals suffering from liver cirrhosis. After excluding brain illness, HE is described as a range of neuropsychiatric disorders in individuals with liver impairment. It is characterized by personality changes, intellectual impairment, and a depressed level of consciousness. Toxins that are typically eliminated from the body by the liver build up in the blood and eventually reach the brain, causing HE. Many signs and symptoms of HE may often be treated if caught early and treated properly. It is important to remember that not everyone who is affected may experience every symptom mentioned below. Affected individuals should speak with their doctor and medical staff about their specific disease, associated symptoms, and general prognosis. Many people only have minor symptoms, known as minimal HE. The exact pathophysiology of HE is still being debated, with the primary theories focusing on neurotoxins, reduced neurotransmission caused by alterations in brain energy metabolism, systemic inflammatory response, and blood-brain barrier (BBB) disturbances in liver failure, as well as metabolic irregularities.
Copyright © 2022, Sharma et al.

Entities:  

Keywords:  ammonia; antioxidant; encephalopathy; lactulose; rifaximin

Year:  2022        PMID: 36134085      PMCID: PMC9470972          DOI: 10.7759/cureus.28016

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  23 in total

Review 1.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

2.  l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.

Authors:  Ming Bai; Zhiping Yang; Xingshun Qi; Daiming Fan; Guohong Han
Journal:  J Gastroenterol Hepatol       Date:  2013-05       Impact factor: 4.029

3.  Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Authors:  P Sort; M Navasa; V Arroyo; X Aldeguer; R Planas; L Ruiz-del-Arbol; L Castells; V Vargas; G Soriano; M Guevara; P Ginès; J Rodés
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

4.  Long Noncoding RNAs Regulate Hyperammonemia-Induced Neuronal Damage in Hepatic Encephalopathy.

Authors:  So Yeong Cheon; Danbi Jo; Young-Kook Kim; Juhyun Song
Journal:  Oxid Med Cell Longev       Date:  2022-02-21       Impact factor: 7.310

Review 5.  Combination therapy for the treatment and prevention of hepatic encephalopathy.

Authors:  Rima A Mohammad; Randolph E Regal; Cesar Alaniz
Journal:  Ann Pharmacother       Date:  2012-10-23       Impact factor: 3.154

Review 6.  Inflammation and hepatic encephalopathy.

Authors:  Iona Coltart; Thomas H Tranah; Debbie L Shawcross
Journal:  Arch Biochem Biophys       Date:  2013-04-10       Impact factor: 4.013

7.  Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

Authors:  Kevin D Mullen; Arun J Sanyal; Nathan M Bass; Fred F Poordad; Muhammad Y Sheikh; R Todd Frederick; Enoch Bortey; William P Forbes
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-21       Impact factor: 11.382

Review 8.  Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis.

Authors:  Debbie L Shawcross; Shabnam S Shabbir; Nicholas J Taylor; Robin D Hughes
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

9.  Osmotic and oxidative/nitrosative stress in ammonia toxicity and hepatic encephalopathy.

Authors:  Boris Görg; Freimut Schliess; Dieter Häussinger
Journal:  Arch Biochem Biophys       Date:  2013-04-06       Impact factor: 4.013

10.  Impaired brain glymphatic flow in experimental hepatic encephalopathy.

Authors:  Anna Hadjihambi; Ian F Harrison; Marta Costas-Rodríguez; Frank Vanhaecke; Natalia Arias; Rocío Gallego-Durán; Svetlana Mastitskaya; Patrick S Hosford; Steven W M Olde Damink; Nathan Davies; Abeba Habtesion; Mark F Lythgoe; Alexander V Gourine; Rajiv Jalan
Journal:  J Hepatol       Date:  2018-09-08       Impact factor: 30.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.